Drug
Inca035784
Inca035784: highest development phase Phase 1, developed by Incyte. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1
- Developer
- Incyte
Trials
| Drug | Phase | Indication |
|---|---|---|
| INCA035784 NCT07008118 | Phase 1 | Myeloproliferative Neoplasms |
Latest
No recent events.
Follow Inca035784 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.